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Objectives To evaluate gender differences in outcomes in 
patents with ST-segment elevation myocardial infarction 
(STEMI) planned for primary percutaneous coronary 
intervention (PPCI).
settings A prespecified gender analysis of the 
multicentre, randomised, double-blind Administration 
of Ticagrelor in the catheterisation Laboratory or in the 
Ambulance for New ST elevation myocardial Infarction to 
open the Coronary artery.
Participants Between September 2011 and October 
2013, 1862 patients with STEMI and symptom duration <6 
hours were included.
Interventions Patients were assigned to prehospital 
versus in-hospital administration of 180 mg ticagrelor.
Outcomes The main objective was to study the 
association between gender and primary and secondary 
outcomes of the main study with a focus on the clinical 
efficacy and safety outcomes. Primary outcome: the 
proportion of patients who did not have 70% resolution 
of ST-segment elevation and did not meet the criteria for 
Thrombolysis In Myocardial Infarction (TIMI) flow 3 at initial 
angiography. Secondary outcome: the composite of death, 
MI, stent thrombosis, stroke or urgent revascularisation 
and major or minor bleeding at 30 days.
results Women were older, had higher TIMI risk score, 
longer prehospital delays and better TIMI flow in the 
infarct-related artery. Women had a threefold higher risk for 
all-cause mortality compared with men (5.7% vs 1.9%, HR 
3.13, 95% CI 1.78 to 5.51). After adjustment, the difference 
was attenuated but remained statistically significant (HR 
2.08, 95% CI 1.03 to 4.20). The incidence of major bleeding 
events was twofold to threefold higher in women compared 
with men. In the multivariable model, female gender was 
not an independent predictor of bleeding (Platelet Inhibition 
and Patient Outcomes major HR 1.45, 95% CI 0.73 to 2.86, 
TIMI major HR 1.28, 95% CI 0.47 to 3.48, Bleeding Academic 
Research Consortium type 3–5 HR 1.45, 95% CI 0.72 to 
2.91). There was no interaction between gender and efficacy 
or safety of randomised treatment.
strengths and limitations of this study
 ► All patients were planned for primary percutaneous 
coronary intervention (PPCI).
 ► Current PPCI techniques and novel antiplatelet 
therapy were used.
 ► Appropriate statistical methods used to adjust for 
baseline differences between genders.
 ► Our analysis, although prespecified, is applicable to 
the population studied.
 ► The large imbalance in the proportion of men and 
women included caused a reduced study power 
for definitely excluding significant differences in 
outcomes.
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Conclusion In patients with STEMI planned for PPCI and treated with 
modern antiplatelet therapy, female gender was an independent predictor 
of short-term mortality. In contrast, the higher incidence of bleeding 
complications in women could mainly be explained by older age and 
clustering of comorbidities.
Clinical trial registration NCT01347580;Post-results.
IntrOduCtIOn
Recent studies have provided evidence of gender differ-
ences in the pathophysiology and the clinical expression 
of atherosclerosis.1 Several registries in patients with 
ST-segment elevation myocardial infarction (STEMI) have 
consistently shown a considerably higher risk of adverse 
outcomes in women compared with men. Nevertheless, 
there are conflicting results regarding whether gender 
is an independent contributor to this observation or the 
higher risk in women depends on differences in baseline 
characteristics and comorbidities between genders.2–8 
Although registries of patients with STEMI usually include 
large, unselected populations, they share some inherent 
limitations. Their results are certainly influenced by 
differences between genders in the use of timely reperfu-
sion therapy and evidence-based drug therapies as well as 
undetected confounding factors.9 10 Therefore, reports of 
gender-based analyses of randomised controlled trials are 
of crucial importance in an effort to minimise inequality 
in the management and evaluate gender as a potential 
independent risk factor for adverse outcome. Only a few 
randomised trials of patients with STEMI treated with 
primary percutaneous coronary intervention (PPCI) 
have reported results in the context of gender.11 12 New 
treatments (eg, ticagrelor or prasugrel), special efforts to 
reduce bleeding (ie, increased use of radial arterial access, 
provisional rather than routine use of glycoprotein (GP) 
IIb/IIIa inhibitor), shorter delay times to reperfusion and 
a growing awareness regarding gender differences in the 
management and importance of adherences to evidence-
based treatment could contribute to improved ischaemic 
and bleeding outcomes in female patients with STEMI.
In the Administration of Ticagrelor in the catheter-
isation laboratory or in the Ambulance for New ST 
elevation myocardial Infarction to open the Coronary 
artery (ATLANTIC) trial, prehospital administration of 
ticagrelor appeared to be safe but did not significantly 
improve outcome compared with in-hospital administra-
tion in patients with STEMI, treated with PPCI according 
to the current modern standards.13
We present a prespecified gender analysis of the 
ATLANTIC trial, with the aim of studying the association 
between gender and outcome.
MethOds
The ATLANTIC study was an international, randomised, 
double-blind, placebo-controlled study with 30 days 
follow-up. The design of the study, inclusion and exclu-
sion criteria, outcome definitions and principal results 
have previously been described.13 14 Briefly, 1862 patients 
presenting with STEMI, <6 hours after symptom onset, 
were included and randomised to prehospital (in the 
ambulance) versus in-hospital (in the catheterisation 
laboratory) treatment with a loading dose of ticagrelor 
(180 mg) in addition to aspirin and standard clinical care. 
All patients were to subsequently receive ticagrelor 90 mg 
twice daily for 30 days, after which it was recommended 
that ticagrelor should be continued for up to 12 months. 
Prehospital administration of a GP IIb/IIIa inhibitor was 
left to the physician’s discretion. Periprocedural use of 
parenteral anticoagulants was also left to the physician’s 
discretion, according to the local practice.
The proportion of patients who did not have ≥70% reso-
lution of ST-segment elevation before PCI and/or did not 
meet the criteria for Thrombolysis In Myocardial Infarc-
tion (TIMI) flow 3 in the infarct-related artery (IRA) 
at initial angiography was the primary outcome of the 
ATLANTIC trial. Secondary outcomes (clinical efficacy 
outcomes) included the composite of death, MI, stent 
thrombosis, stroke or urgent revascularisation at 30 days 
and definite stent thrombosis at 30 days. Safety outcomes 
included major and minor bleeding over the 30-day 
treatment period. Bleeding risk was evaluated using the 
TIMI, Bleeding Academic Research Consortium (BARC) 
and Study of Platelet Inhibition and Patient Outcomes 
(PLATO) bleeding definitions.14
The main objective of our analysis was to study the 
association between gender and primary and secondary 
outcomes of the main study with a special focus on the 
clinical efficacy and safety outcomes. The interaction of 
gender subgroups with randomised treatment effects was 
also investigated.
The trial design and protocol were approved by the 
national regulatory authorities in all the participating 
countries and by the local ethics committee or institu-
tional review board at each participating site. All patients 
provided written informed consent.
stAtIstICAl AnAlysIs
Continuous variables are presented by their mean and 
SD or median and 25th−75th percentiles as appropriate. 
Categorical variables are presented as counts and percent-
ages. Baseline and periprocedural characteristics were 
compared according to gender by χ2 tests for categor-
ical variables and Student's t-test or Mann-Whitney U test 
for continuous variables, depending on if the variable of 
interest was normally distributed or not. A p value <0.05 is 
considered to indicate statistical significance.
The incidence of events over time by gender is presented 
by Kaplan-Meier curves.
In order to study the association between gender and 
the clinical efficacy and safety outcomes, independent of 
randomised treatment as well as the possible interactions 
between gender and randomised treatment with respect 
to the outcomes, HRs with 95% CIs were derived from 
Cox proportional hazards models. In the unadjusted 
 3Venetsanos D, et al. BMJ Open 2017;7:e015241. doi:10.1136/bmjopen-2016-015241
Open Access
(crude) model, gender was the only explanatory variable 
whereas in the adjusted multivariable model, gender was 
forcibly included and the other variables were chosen by 
using a forward stepwise selection algorithm with a signif-
icant cut-off level of 0.05 for inclusion. Selection of covari-
ates included in the multivariable analysis was based on 
previous studies3 4 6 15 and clinical experience. Univariate 
analysis was not performed. However, this is a common 
practice in observational studies and we included 18 
covariates in our multivariable analysis that, we believe, 
incorporated all possible predictors of adverse outcomes 
in a STEMI population.
Adjustment variables included age, weight, prior MI, 
prior PCI, patient's history of diabetes, hypertension, 
non-haemorrhagic stroke, gastrointestinal bleeding, time 
from symptom onset to pre-PCI ECG, admission Killip 
class (as a dichotomous variable 1/>1), baseline haemo-
globin, estimated glomerular filtration rate (eGFR) 
according to the Modification of Diet in Renal Disease 
(MDRD) formula, access site, use of GP IIIb/IIa inhibitor, 
bivalirudin and unfractionated heparin (UFH), location 
of MI and revascularisation. To evaluate the importance of 
early mortality, a landmark analysis of the clinical efficacy 
outcomes was also performed from 48 hours after rando-
misation (arbitrarily defined) to the end of the study. In 
order to explore the importance of bleeding on the clinical 
efficacy outcomes, a separate analysis was also performed 
by censoring the patients who reported a PLATO major 
bleeding at the time of the onset of a bleeding event.
A comparable statistical process was used to compare 
gender differences in the effect of randomised treat-
ment by constructing logistic regression models. ORs 
with 95% CIs were presented. The above process for Cox 
regression and logistic regression was also used to explore 
the interaction effect of gender and treatment.
For most of the variables included in the multivariable 
models, only few patients had missing data (<10 patients). 
However, 7% of patients had missing values for creati-
nine, 5% for haemoglobin and 4% for Killip class. The 
number of patients with complete data for multivariable 
Cox proportional hazard models of the primary outcome 
was 1613 (88%).
All the analyses were performed using SAS v.9.3.
results
baseline and periprocedural characteristics stratified by 
gender
Demographic and clinical characteristics
The study population consisted of 369 (20%) women. 
They were older (mean age 69 vs 59 years, p<0.01), had 
lower body mass index (BMI), higher TIMI risk score, 
more often had a history of hypertension, chronic 
obstructive pulmonary disease and stroke. Men had more 
frequent prior PCI. No difference was observed between 
genders with respect to acute heart failure (Killip class 
>1) and only a minority of patients presented with cardio-
genic shock (table 1).
Time delays
Women had significantly longer delay times, both from 
symptom onset to prehospital ECG (median 88 vs 70 min, 
p<0.01) and from pre-PCI to post-PCI angiography 
(median 36 vs 32 min, p=0.03).
Procedural characteristics, angiographic findings and medication 
during the index event
Coronary angiography was more often performed by 
femoral access in women (39.7% vs 30.4%, p<0.01). The 
genders did not differ according to IRA, with the left ante-
rior descending artery involved in 38% of women and 
39% of men. PPCI, with or without stent, was performed 
significantly more often in men (88.5% vs 83.7%, p<0.01), 
whereas the use of drug-eluting stents was similar. Throm-
boaspiration, GP IIb/IIIa inhibitors and intravenous anti-
coagulants were used less often in women (table 1).
Association between gender and outcomes independent of 
randomised treatment
Female gender was associated with significantly higher 
risk for the composite outcome of death, MI, stroke, 
urgent revascularisation or definite acute stent throm-
bosis compared with male gender (6.8% vs 3.9%, crude 
HR 1.79, 95% CI 1.12 to 2.86) (figure 1). This difference 
was mainly driven by a threefold higher risk for all-cause 
mortality in women compared with men (5.7% vs 1.9%, 
HR 3.13, 95% CI 1.78 to 5.51). Although the difference 
was attenuated in the multivariable model, gender was 
still associated with all-cause mortality at 30 days (HR 2.08, 
95% CI 1.03 to 4.20) (figure 2 and table 2). Landmark 
analysis for events occurring within 48 hours, and between 
48 hours and 30 days showed that 38% of the women and 
36% of the men who did not survive the first month died 
within 48 hours. Comparison after excluding patients 
from further analysis at the time point of a PLATO major 
bleeding event still revealed a statistically significant asso-
ciation between women and all-cause mortality (4.3% vs 
1.4%. HR 3.20, 95% CI 1.67 to 6.13). Similar result was 
obtained after adjustment but the difference between 
genders did not reach statistical significance (HR 2.15, 
95% CI 0.93 to 5.00).
Female gender was associated with lower risk for TIMI 
flow <3 in the IRA at initial angiography (adjusted OR 
0.67, 95% CI 0.47 to 0.96). The risk of incomplete ST-seg-
ment elevation resolution (<70%) before PCI did not 
differ significantly between the genders (adjusted OR 
1.11, 95% CI 0.73 to 1.71). The risk of abnormal TIMI flow 
in the IRA and incomplete ST-segment elevation resolu-
tion after PCI was similar in both genders (figure 3).
Women had significantly higher risk for major bleeding 
complications compared with men, irrespective of the 
bleeding definition used (30-day PLATO major bleeding 
4.6% vs 2.2%, HR 2.15, 95% CI 1.18 to 3.85, TIMI major 
bleeding at 30 days 2.7% vs 0.9%, HR 2.95, 95% CI 1.31 
to 6.65, BARC type 3–5 bleeding 4.3% vs 2.1%, HR 2.15, 
95% CI 1.18 to 3.93) (figure 4). However, after adjust-
ment for baseline and clinical characteristics, female 
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Table 1 Baseline, clinical and periprocedural characteristics according to gender
Characteristics Women (n=369) Men (n=1493) p Value
Age, years; mean (SD) 69 (13.0) 59 (11) <0.01
Age ≥75 years 153 (41.5) 151 (10.1) <0.01
BMI, kg/m2; median (IQR) 25.6 (22.5–29.1) 26.5 (24.3–29.4) <0.01
Patient's history of:
  Diabetes mellitus 48 (13.0) 205 (13.7) 0.72
  Hypertension 190 (51.5) 605 (40.5) <0.01
  Dyslipidemia 117 (31.7) 536 (35.9) 0.13
  Angina 36 (9.8) 157 (10.5) 0.67
  Prior myocardial infarction 24 (6.5) 135 (9.0) 0.67
  Prior PCI 16 (4.3) 124 (8.3) <0.01
  Prior CABG 1 (0.3) 11 (0.7) 0.32
  Prior non-haemorrhagic stroke 8 (2.2) 10 (0.7) <0.01
  Chronic obstructive pulmonary disease 22 (6.0) 54 (3.6) 0.04
  Gastrointestinal bleeding 1 (0.3) 16 (1.1) 0.15
  Chronic renal disease 7 (1.9) 27 (1.8) 0.91
Index event information
  First medical contact in ambulance 280 (75.9) 1132 (75.8) 0.24
  Minutes from symptom onset to prehospital ECG, median 
(IQR)
88 (49–169) 70 (41–129) <0.01
  Minutes from prehospital ECG to PCI, median (IQR) 83 (68–101) 80 (66–96) 0.03
  Minutes from pre-PCI angiography to post-PCI 
angiography, median (IQR)
36 (24–52) 32 (23–45) 0.03
  Received first loading dose 369 (100) 1488 (99.7) 0.27
Risk level at admission
  Killip class
   I 332 (90.0) 1349 (90.4) 0.82
   IV 2 (0,5) 3 (0.2)
  TIMI risk score
   0–2 119 (32.2) 1006 (67.4) 0.01
   3–6 231 (62.6) 471 (31.5)
   >6 19 (5.1) 16 (1.1)
  Culprit vessel
  Left main artery 4 (1.1) 18 (1.2) 0.63
  Left anterior descending artery 141 (38.8) 571 (39.0)
  Right coronary artery 150 (41.3) 590 (40.3)
  Left circumflex 39 (10.7) 196 (13.4)
  No culprit vessel identified 28 (7.7) 85 (5.8)
  Normal coronary angiography 27 (7.4) 76 (5.2) 0.1
Procedures for index event
  Femoral access 144 (39.7) 445 (30.4) <0.01
  Thromboaspiration 160 (43.4) 781 (52.3) <0.01
  PCI 309 (83.7) 1321 (88.5) 0.01
   With any stent 288 (78.0) 1248 (83.6) 0.01
   With DES 185 (50.1) 761 (51.0) 0.77
  Coronary artery bypass grafting 4 (1.1) 21 (1.4) 0.63
Continued
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gender was no longer an independent predictor of risk 
for bleeding at 30 days (table 2 and figure 2).
Association between gender and efficacy and safety of 
randomised treatment
Prehospital administration of ticagrelor compared with 
in-hospital administration resulted in a non-significant 
difference in the primary, secondary and safety outcomes. 
No significant interactions between randomised treat-
ment and gender in terms of these outcomes were found 
in the unadjusted or adjusted model (test for interaction 
in the multivariable models; p=0.94 for all-cause mortality, 
p=0.55 for absence of TIMI flow grade 3 in the IRA at 
initial angiography, p=0.71 for absence of ≥70% reso-
lution of pre-PCI ST-segment elevation, and p=0.31 for 
TIMI major bleeding at 30 days) (see online supplemen-
tary tables 1–3).
dIsCussIOn
In the present analysis, unadjusted data showed a signifi-
cantly higher risk of short-term mortality and bleeding 
complications in women. After multivariable adjustment 
female gender remained an independent predictor of 
mortality, whereas advanced age and comorbidities could 
mainly explain the higher incidence of bleeding compli-
cations in women.
Undoubtedly, older age and clustering of comorbidi-
ties in women could explain a large part of the observed 
difference in short-term clinical outcomes in our study. 
However, the adjusted risk for death was still significantly 
higher in women. The contribution of gender, as inde-
pendent risk factor, on adverse outcome may depend on 
the population studied. The age gap between genders 
in our population was substantially higher compared 
with previous studies, with a mean age difference of 10 
years.12 16 In spite of appropriate statistical methods that 
were used for adjustment, adjustment for such age differ-
ence is awkward. Additionally, the age difference may 
indicate a selection bias. As identification and randomi-
sation took place in the ambulance, young women with 
suspected STEMI were possibly not included in the study 
as alternative reasons for ST-segment elevation on prehos-
pital ECG may have been considered more plausible in 
this group. Furthermore, a trend towards increased 
mortality with prehospital ticagrelor was observed in the 
ATLANTIC trial that was mainly attributed to a plausible 
imbalance between the two groups in terms of the severity 
of the presenting event. Given the low rate of all-cause 
mortality, unobserved confounders in elderly women 
with STEMI may have significantly contributed to our 
results and the findings of the main study. These factors 
may have a significant impact on the remaining higher 
adjusted risk for short-term mortality in women.
Previous observational studies in STEMI cohorts, 
without focus on patients treated with PPCI have shown a 
higher risk for early mortality in women.6 17 18 Significant 
differences in the rate of reperfusion therapy between 
genders and hidden confounders such as frailty in elderly 
Characteristics Women (n=369) Men (n=1493) p Value
  No revascularisation 56 (15.2) 151 (10.1) <0.01
Any glycoprotein IIb/IIIa inhibitor use 115 (31.2) 598 (40.1) <0.01
Glycoprotein IIb/IIIa inhibitor use before angiography 14 (3.8) 116 (7.8) <0.01
Intravenous anticoagulant prior to pre-PCI angiography 231 (62.6) 1027 (68.8) 0.02
Intravenous anticoagulant during hospitalisation* 310 (84.0) 1332 (89.2) <0.01
  Heparin only 135 (36.6) 584 (39.1) 0.02
  Bivalirudin only 29 (7.9) 65 (4.4) 0.02
Variables presented as numbers (percentages) unless otherwise indicated.
*Includes all intravenous medications given on the date of the qualifying ECG and/or index PCI.
BMI, body mass index; CABG, coronary artery bypass grafting; DES, drug-eluting stent; PCI, percutaneous coronary intervention; TIMI, 
Thrombolysis In Myocardial Infarction.
Table 1 Continued 
Figure 1 Cumulative Kaplan-Meier (KM) estimates of 
the incidence of the composite endpoint (EP) of death, 
MI, stroke, urgent revascularisation or definite acute stent 
thrombosis and all-cause mortality at 30 days by gender.
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women with STEMI may have influenced their results. 
Recent observational studies including patients treated 
with PPCI4 19 20 and prespecified gender analysis of 
randomised controlled trials11 12 16 21 22 have shown that the 
impact of gender on mortality could mainly be explained 
by differences in age and comorbidities between genders. 
On the contrary, an observational study and a meta-analysis 
have reported higher multivariable adjusted risk of early 
Figure 2 Association between gender and clinical efficacy and safety outcomes independent of randomised treatment.
Table 2 Association between gender and clinical outcomes independent of randomised treatment
Outcomes
Female (n=369) Male (n=1489)




(n included=1613) p Value *
Patients with end 
point, n (%)
Patients with end 
point, n (%)
Mortality and cardiovascular outcomes
  Composite of death/MI/stroke/urgent 
revascularisation/definite acute stent 
thrombosis
25 (6.8) 58 (3.9) 1.79 (1.12to 2.86) 1.32 (0.77to 2.27) 0.32
  Composite of death/MI/urgent 
revascularisation
23 (6.2) 50 (3.4) 1.91 (1.17 to 3.13) 1.33 (0.75to 2.36) 0.32
  All-cause mortality 21 (5.7) 28 (1.9) 3.13 (1.78 to 5.51) 2.08 (1.03to 4.20) 0.04
  Myocardial infarction 3 (0.8) 14 (0.9) 0.90 (0.26to 3.13) 0.82 (0.23to 2.85) 0.76
  Stroke 3 (0.8) 3 (0.2) 4.18 (0.84to 20.70) 4.14 (0.84to 20.51) 0.08
  Urgent revascularisation 2 (0.5) 11 (0.7) 0.75 (0.17to 3.38) 0.69 (0.15to 3.11) 0.63
  Definite acute stent thrombosis 3 (0.8) 10 (0.7) 1.23 (0.34to 4.49) 1.29 (0.35to 4.76) 0.70
  Acute stent thrombosis (definite or 
probable)
11 (3.0) 30 (2.0) 1.53 (0.77to 3.05) 0.88 (0.39to 1.98) 0.76
Safety outcomes
  PLATO major bleeding† 17 (4.6) 33 (2.2) 2.15 (1.20to 3.85) 1.45 (0.73to 2.86) 0.29
  TIMI major bleeding† 10 (2.7) 14 (0.9) 2.95 (1.31to 6-65) 1.28 (0.47to 3.48) 0.63
  TIMI major or minor bleeding† 18 (4.9) 54 (3.6) 1.38 (0.81to 2.35) 0.94 (0.51to 1.74) 0.85
  BARC type 3–5 (major) bleeding† 16 (4.3) 31 (2.1) 2.15 (1.18to 3.93) 1.45 (0.72to 2.91) 0.30
  BARC type 2–5 (major or minor) 
bleeding†
20 (5.4) 56 (3.8) 1.48 (0.89to 2.47) 1.03 (0.57to 1.84) 0.93
*HR (for female vs male) and p value calculated from logistic regression model including gender, age, weight, prior myocardial infarction, prior 
percutaneous coronary intervention, diabetes, hypertension, non-haemorrhagic stroke, gastrointestinal bleeding, time from symptom onset to 
prehospital ECG, admission Killip class, baseline haemoglobin, estimated glomerular filtration rate, access site, glycoprotein IIb/IIIa inhibitor, 
bivalirudin or unfractionated heparin use during index procedure, revascularisation and location of myocardial infarction
†Non-CABG-related bleeding occurring up to the date of the last study visit (to the maximum of 32 days) are included in the table.
BARC, Bleeding Academic Research Consortium; CABG, coronary artery bypass grafting; MI, myocardial infarction; PLATO, Study of Platelet 
Inhibition and Patient Outcomes; TIMI, Thrombolysis in Myocardial Infarction.
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mortality in women with STEMI treated with PPCI.23 24 
Differences in the population studied and in the covari-
ates included in the multivariable analysis between studies 
may explain the conflicting results. Previous studies have 
clearly demonstrated the importance of body surface 
area and the eGFR on prognosis.25 26 In a meta-analysis, 
Berger et al showed that female gender was an indepen-
dent predictor of early mortality in patients with STEMI. 
However, 30-day mortality was not statistically significant 
different between genders after additional adjustment for 
angiographic disease severity.27
In the present study, women had two to three times 
higher unadjusted risk for non-CABG-related bleedings, 
depending on the definition used. After adjustment 
for baseline characteristics, no significant difference 
remained. Female gender has previously been associated 
with higher risk for bleeding complications in patients 
with acute coronary syndrome.28–31 Known predictors 
of bleedings like advanced age, diabetes, hypertension, 
renal insufficiency and anaemia, are usually more often 
encountered in women with STEMI.15 Additionally, 
smaller body and vessel size, higher use of femoral access 
and overdosing of antithrombotic medication in women 
may explain the higher observed risk for bleeding. Proce-
dural-related improvement such as increased use of 
radial access or smaller femoral sheaths and careful dose 
adjustment of antithrombotic medication, have resulted 
in a significant decline in the risk of bleeding/vascular 
complication during cardiovascular interventions the last 
years and have probably contributed to our results.32 The 
negative impact of bleedings on prognosis in patients with 
STEMI is well established.15 Our data showed that even 
after excluding patients from further analysis at the time 
of a PLATO major bleeding, the HR for early mortality 
in women versus men remained unchanged, implying 
that reducing the rate of major bleeding in women may 
improve their prognosis but is not the main reason for 
the observed difference between genders in the early 
mortality.
Some well-known gender disparities in the concom-
itant management of patients with STEMI remained 
unchanged. Women were less likely to be treated with GP 
IIb/IIIa inhibitors and thromboaspiration during PPCI 
despite lack of gender difference in protection from 
major adverse outcomes by GP IIb/IIIa inhibitors33 and 
benefit of thromboaspiration at the time when the study 
was conducted.34 Similar findings have been provided 
by large registries.7 8 Some of these lower rates of utili-
sation may be ‘appropriate’ given the higher TIMI 3 
flow rates in the IRA pre-PPCI and lower rates of PPCI 
in women versus men. Furthermore, physician’s concern 
for higher risk of bleeding in older women with STEMI 
have certainly contributed to the lower use of GP IIb/IIIa 
inhibitors in women.
Although the impact of early reperfusion on mortality 
in patients with STEMI is now unquestionable,35 patients’ 
delay from symptom onset to prehospital ECG was not an 
independent predictor of mortality in our study, in agree-
ment with results from previous gender analyses.36 37 A 
plausible explanation is an association between age and 
delay, and thus adjustment for age minimises the relative 
impact of delay. Furthermore, in PPCI, female gender 
has been associated with similar or even smaller infarct 
size than that in male gender, despite longer prehospital 
delays, indicating that other factors than larger infarct size 
secondary to longer prehospital delay mainly contribute 
Figure 3 Association between gender and primary and secondary outcomes, independent of randomised treatment.
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to the observed higher unadjusted short-term mortality.36 
The proportion of 30-day mortality that occurred 
within 48 hours of admission was similar in women and 
men (38% vs 36%, respectively) contrasting previous 
data where gender differences in early mortality were 
accounted for by excess very early (within 24–48 hours) 
deaths in women with STEMI.7 18 Cardiogenic shock and 
haemodynamic instability were key exclusion criteria in 
the ATLANTIC trial, which may have influenced these 
results. Cardiogenic shock has been shown to be more 
common in women and female gender has been highly 
associated with mortality in shock patients.20
In terms of ST-segment elevation resolution and TIMI 
flow 3 rates before and after PCI, no significant difference 
between genders was observed apart from a lower risk of 
abnormal coronary flow in IRA at initial angiography in 
women. The higher rate of TIMI flow 3 at initial angi-
ography may be explained by the higher rate of normal 
coronary arteries as well as the less obstructive coronary 
artery disease in women with STEMI, which is in concor-
dance with previous data.37
The analysis of the effect of gender on outcomes depen-
dent on the randomised treatment showed no statistically 
significant interactions. Prehospital administration of 
ticagrelor did not improve pre-PCI or post-PCI coronary 
reperfusion as assessed by TIMI flow in IRA and resolu-
tion of ST elevation pre-PCI. Clinical efficacy outcomes 
were not significantly improved either. However, prehos-
pital administration of ticagrelor was safe in both genders 
with similar rate of major and minor bleedings.
strengths And lIMItAtIOns
The present study has some important limitations. Our 
results are applicable to the populations studied, patients 
with STEMI pretreated with ticagrelor and planned for 
primary PCI.
The ATLANTIC study population is from a randomised 
controlled trial, with inclusion and exclusion criteria 
contributing to differences relative to populations treated 
in routine clinical practice, and thereby limiting general-
isability. However, the proportion of elderly patients (>75 
years) was higher than in the PLATO trial, especially for 
women, and under-representation of women in clinical 
trials is a well-recognised problem. Moreover, the study 
was conducted at several centres and countries increasing 
external validity. Taken together, our results should be 
applied to a real-world STEMI population with caution.
Additionally, the ATLANTIC trial was not stratified by 
gender. The large imbalance in the proportion of men 
and women included, commonly encountered in a STEMI 
population, caused a reduced power for detecting or defi-
nitely excluding significant differences in some outcomes 
between the genders or to definitely exclude an interac-
tion between gender and the randomised treatment.
The most important strength of our analysis is that 
patients were treated according to the current guidelines 
of STEMI, with PPCI as the reperfusion strategy of choice, 
administration of the modern ADP receptor blocker tica-
grelor in addition to aspirin as soon as possible after the 
first medical contact, high use of radial access during 
catheterisation and adjuvant pharmacological treatment 
during PPCI with UFH or bivalirudin.38 Therefore, our 
study provides important information about differences 
and similarities between genders in patients with STEMI 
treated with current PCI techniques and pharmacological 
treatment.
COnClusIOn
In patients with STEMI, planned for PPCI and treated 
with modern antiplatelet therapy, female gender identi-
fies a group of patients with high risk of early mortality in 
whom prompt efforts to improve outcome are warranted. 
Female gender was not an independent predictor of 
bleeding but advanced age and clustering of comorbid-
ities in women could mainly explain their higher unad-
justed risk for bleeding events compared with men. 
Prehospital administration of ticagrelor had a similar effi-
cacy and safety profile in men and women with STEMI.
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